Central FGF1 injections preserve β-cell function and increase hepatic glucokinase activity, both of which may underlie the remission of hyperglycemia in diabetic rodent models (6, 8); however, whether the DVC is involved in the metabolic actions of FGF1 or if neurons within this region respond to FGF1 is unknown (21–24). The gene discussed is FGF1; the disease is Hyperglycemia.